Magnesium for advanced lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests if adding magnesium supplements to standard first-line treatment (chemotherapy plus immunotherapy) improves outcomes for people with advanced non-small cell lung cancer (NSCLC) that has spread or cannot be removed by surgery. It is for patients who have not had prior treatment for metastatic disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have advanced non-small cell lung cancer (NSCLC) that is stage III (unresectable) or stage IV (metastatic) and cannot be cured with surgery or chemoradiotherapy alone.
- You must be about to start your first systemic treatment for metastatic disease, which will be a carboplatin-based chemotherapy combined with an immunotherapy (PD-1 or PD-L1 inhibitor).
- You must not have certain gene changes in your tumor (like EGFR, ALK, ROS1, etc.) that would allow a different targeted therapy.
- You must be at least 18 years old and have a good performance status (ECOG 0 or 1), meaning you are fully active or only limited in physically strenuous activity.
- Your kidney function must be adequate (eGFR at least 45), and you must not have very low or very high magnesium levels in your blood.
- You cannot have used oral or intravenous magnesium in the 14 days before enrollment, and must be willing to stop any magnesium supplements (including over-the-counter) during the trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding a fiber supplement to standard immunotherapy can help treat advanced non-small cell lung cancer. It's for people whose tumors have high PD-L1 levels and no treatable genetic mutations.
This trial tests a lower starting dose of the targeted therapy drug lazertinib combined with magnesium supplements to prevent a common side effect (peripheral neuropathy) in people with advanced lung cancer caused by certain EGFR mutations. The goal is to see if this approach keeps the drug effective while reducing nerve damage symptoms like numbness or tingling.
This early study tests whether replacing magnesium—either by diet or a topical (skin) supplement—can improve safety or other health measures in people with lymphoma. It focuses on people who have a slightly low magnesium level and checks blood magnesium repeatedly during the study.
This trial tests a new drug called SSGJ-706, either alone or with other treatments, for people with advanced non-small cell lung cancer (NSCLC) that has spread or cannot be surgically removed. The goal is to see if it helps shrink or control the cancer.
This trial tests a new way of giving radiation (in high and low doses) together with chemotherapy and immunotherapy to treat advanced non-small cell lung cancer. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial studies whether adding special nutrition (oral immunonutrition supplements) can help immunotherapy work better in people with metastatic non-small cell lung cancer. Participants receive immunotherapy, with or without chemotherapy, and must be able to take oral supplements.
Hear when a new Metastatic NSCLC - Non-Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.